Clinical Scorecard: The Impact of SGLT2 Inhibitors on the Progression of Diabetic Retinopathy: Insights from a Retrospective Cohort Study and Mendelian Randomization Analysis

At a Glance

Key Highlights

• SGLT2i+INS associated with lower risk of DR progression (HR = 0.40, P = 0.016).
• Cumulative incidence of DR progression reduced in SGLT2i+INS group (log-rank P = 0.032).
• Exploratory OCTA-based nomogram showed modest performance (C-index=0.705).
• Mendelian randomization supported association between genetically proxied SGLT2 and DR risk (OR = 1.21, P = 0.009).
• Nine metabolites and five plasma proteins showed potential mediation evidence.

Guideline-Based Recommendations

Diagnosis

• Assess retinal microvascular parameters using SS-OCTA.

Management

• Consider SGLT2 inhibitors in combination with insulin for patients with type 2 diabetes to potentially reduce DR progression.

Monitoring & Follow-up

• Regular ophthalmic examinations for patients with diabetes to monitor for DR and DME.

Risks

• Exclude patients with other ocular diseases or severe systemic diseases that may confound results.

Patient & Prescribing Data

Insulin-treated patients with type 2 diabetes.

SGLT2 inhibitors may offer advantages over sulfonylureas in reducing the risk of DR progression.

Clinical Best Practices

• Utilize SS-OCTA for early detection of microvascular changes in diabetic patients.
• Monitor glycemic control and other risk factors in patients with diabetes to mitigate DR progression.

Related Resources & Content

• Study Protocol